Thailand Inflation Remains Negative for 10th Straight Month in January 
Federal Reserve Faces Subpoena Delay Amid Investigation Into Chair Jerome Powell 
New York Judge Orders Redrawing of GOP-Held Congressional District 
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
U.S. Condemns South Africa’s Expulsion of Israeli Diplomat Amid Rising Diplomatic Tensions 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
